Media OutReach

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Published

3 weeks ago

24/03/2025

GUANGDONG, CHINA AND BAGSVÆRD, DENMARK – Media OutReach Newswire – 24 March 2025 – The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251. United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan. United Biotechnology is eligible to receive an upfront payment of 200 million US dollars and potential milestone payments of up to 1.8 billion dollars from Novo Nordisk, as well as tiered royalties on net sales outside of Chinese mainland, Hong Kong, Macau, and Taiwan.

“Novo Nordisk is dedicated to providing improved treatment options for people living with obesity, type 2 diabetes, and other cardiometabolic diseases. The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment options that cater to the diverse needs of people living with these highly prevalent diseases,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “We look forward to building on United Biotechnology’s scientific work and further exploring the potential best-in-class properties of UBT251 across cardiometabolic disease indications.”

United Biotechnology recently completed a randomized, double-blind, placebo-controlled phase 1b trial in China designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple subcutaneous injections of UBT251 in people with overweight or obesity.

A total of 36 patients were enrolled in three different dose groups (1mg, 1mg/3mg, 1mg/3mg/6mg). Each group adopted a dose titration method, with subcutaneous injection once a week for 12 consecutive weeks.

The safety profile of UBT251 was consistent with incretin-based therapies. The most common adverse events were gastrointestinal and the vast majority were mild to moderate in severity. In the highest dose group, the average weight of the people who completed the trial decreased by 15.1% from baseline, while the average weight of people in the placebo group increased by 1.5% from baseline.

“We are pleased to announce our exclusive license agreement with Novo Nordisk for UBT251. As a leading global biopharmaceutical company, Novo Nordisk holds a strong position in the treatment of chronic diseases,” said Mr. Tsoi Hoi Shan, the Chairman of TUL. “TUL is committed to strengthening its presence in the treatment of chronic diseases, including endocrine and metabolic disorders, while actively expanding its footprint in global markets. We believe that Novo Nordisk’s expertise will play a key role in accelerating the global development of UBT251.”

This collaboration represents a pivotal milestone in TUL’s ongoing efforts to establish a global strategic presence and demonstrates its commitment to innovation-driven transformation. TUL will continue to foster scientific innovation, advance high-quality and sustainable development, and accelerate the establishment of a globally competitive framework for manufacturing, R&D, and commercialization.

The closing of this transaction is subject to applicable regulatory clearance and other customary closing conditions.
Hashtag: #TUL

The issuer is solely responsible for the content of this announcement.

About UBT251

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has demonstrated potent activity on all three receptors in a preclinical setting.

UBT251 is categorized as a Class 1 innovative drug in China, being developed by United Biotechnology for multiple indications. To date, UBT251 has been approved for clinical trials in China in adult type 2 diabetes, overweight or obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), and chronic kidney disease (CKD), and for clinical trials in the United States in adult type 2 diabetes, overweight or obesity, and CKD.

United Biotechnology recently initiated a phase 2 trial for UBT251 in people with overweight or obesity in China.

About TUL and United Biotechnology

Founded in 1990, TUL (HKEX: 3933) is mainly engaged in the research and development, production and sales of pharmaceuticals, and ranks among the leading integrated pharmaceutical companies in China. TUL currently boasts seven production bases, covering intermediate products, bulk medicine , finished products, veterinary drugs, empty capsule casings, and medical devices, with the sales networks dotted across nearly 80 countries and regions. United Biotechnology, located in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, serves as the biopharmaceutical R&D headquarter of TUL. United Biotechnology focuses on the development of high-end biopharmaceuticals to treat major chronic diseases. For more information, please visit www.tul.com.cn.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.

Media OutReach

In record time: Octa broker on how speed inspires trust

Published

11 hours ago

15/04/2025

Media Outreach

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 15 April 2025 – In online trading, speed is king. Below, the experts at Octa, a regulated and trusted broker since 2011, break down the aspects of trading where speed matters most and offer an accessible way to accelerate trading progress.

The modern world revolves around speed and solutions that solve problems faster than their predecessors. Speed advantage determines success in many industries and areas of life: information delivery, financial transactions, manufacturing, sports, and many more. This is especially true about all things digital, particularly online trading, where delays are considered a serious red flag by the modern consumer.

Why modern trading is all about speed

For modern traders, the broker’s ability to provide efficient order execution, fast withdrawals, and timely customer service are the key requirements for building trust. Without speed, a broker can hardly expect to establish long-term client relationships. Moreover, in the financial sector, speed comes in many forms.

The e-brokerage industry entirely depends on high-speed data feeds and information transfers executed with millisecond precision. Retail traders who operate from their desktops or mobile devices find navigating the markets proportionately easier if they are fast enough where and when it counts.

In online trading, especially in scalping or intraday trading with lesser timeframes, a breakout, reversal, or reaction to a news release can happen in seconds. Delayed order execution, a stuttering trading platform, or suspended reaction due to incomplete information can easily turn a low-risk, high-probability trade into a risky venture with an uncertain outcome.

Where in trading speed makes the most difference

Traders emphasise the importance of strategy, but it is the execution that often separates a positive outcome from a negative one. Choosing the right price movement direction is ineffective unless the action is taken on time. Fast execution results in less slippage, better prices, tighter spreads, and greater control over trading risks.

Another speed-related factor that determines a positive trading experience and is, therefore, highly valued by traders is withdrawal speed. Octa broker’s recent survey shows that the ability to withdraw their funds without hiccups is one of the main reasons traders choose one broker over another.

Octa broker uses its global reach to establish close cooperation with various payment providers and systems. This way, Octa offers some of the fastest withdrawals on the market while avoiding any hidden charges. All the broker’s fees are reflected in its terms and conditions and can be reviewed in advance.

CFDs: a perfect instrument for modern-day trading

Contracts for difference, or CFDs, are well-known for speed and flexibility. Instead of buying an asset or a futures contract with delivery obligations, CFDs involve trading price movement, and that makes the entire transaction faster and more direct.

CFDs enable traders to profit from upward and downward market movements without restrictions. There is no need to wait for a market surge or borrow from an exchange when going short, as is often the case with crypto trading. This flexibility is especially advantageous in fast-moving markets, where direction can reverse in seconds.

Another advantage of CFDs is tight spreads and direct market access, which ensures that the displayed prices are among the most competitive in the market. Trades are executed without interference, eliminating delays and improving the chances of getting filled at or near the intended price.

Last but not least, CFDs provide multiple leverage options, which, if used wisely, can significantly increase a trader’s potential, albeit at the cost of increased exposure. Leverage allows traders to capitalise on short bursts of volatility instead of waiting for a major directional move to turn a profit.

Modern trading is driven by speed, efficiency, and transparency. Brokers build trust by allowing traders to operate efficiently in a high-frequency environment and act on volatility without delay. By ensuring fast withdrawals and a transparent, clearly communicated fee structure, brokers facilitate a seamless trading journey for their clients, contributing to their success in a vibrant environment where speed reigns supreme.
___

Disclaimer: This content is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to engage in any investment activity. It does not take into account your investment objectives, financial situation, or individual needs. Any action you take based on this content is at your sole discretion and risk. Octa and its affiliates accept no liability for any losses or consequences resulting from reliance on this material.

Trading involves risks and may not be suitable for all investors. Use your expertise wisely and evaluate all associated risks before making an investment decision. Past performance is not a reliable indicator of future results.

Availability of products and services may vary by jurisdiction. Please ensure compliance with your local laws before accessing them.

Hashtag: #Octa

The issuer is solely responsible for the content of this announcement.

Octa

Octa is an international CFD broker that has been providing online trading services worldwide since 2011. It offers commission-free access to financial markets and various services used by clients from 180 countries who have opened more than 52 million trading accounts. To help its clients reach their investment goals, Octa offers free educational webinars, articles, and analytical tools.

The company is involved in a comprehensive network of charitable and humanitarian initiatives, including the improvement of educational infrastructure and short-notice relief projects supporting local communities.

In Southeast Asia, Octa received the ‘Best Trading Platform Malaysia 2024’ and the ‘Most Reliable Broker Asia 2023’ awards from Brands and Business Magazine and International Global Forex Awards, respectively.

Media OutReach

2023 VinFuture Special Prize Laureate Prof. Daniel Drucker: Ample room remains for innovation in GLP-1 therapies

Published

22 hours ago

14/04/2025

Media Outreach

HANOI, VIETNAM – Media OutReach Neswire – 14 April 2025 – Together with world-renowned scientists including Prof. Joel F. Habener, Prof. Jens Juul Holst and Assoc. Prof. Svetlana Mojsov, Prof. Daniel Drucker at the University of Toronto and the Lunenfeld-Tanenbaum Research Institute, has discovered the role of glucagon-like peptide-1 (GLP-1), leading to life-changing therapies for people with diabetes and obesity while stimulating emerging applications for neurodegenerative diseases. This groundbreaking innovation has garnered significant recognition for him and the GLP-1 research group, exemplified by the prestigious 2023 VinFuture Special Prize for Innovators with Outstanding Achievements in Emerging Fields, and the 2025 Breakthrough Prize in Life Sciences, awarded earlier this April.

Prof. Daniel Drucker, 2023 VinFuture Special Prize Laureate for Innovators with Outstanding Achievements in Emerging Fields, continues to receive recognition with the 2025 Breakthrough Prize in Life Sciences

In this interview, he reflects on the impact and influences of the VinFuture Prize on his further research, as well as the challenges and prospects of expanding GLP-1 accessibility. As global scientific recognition continues to evolve, he shares insights into the vital role of initiatives like the VinFuture Prize in inspiring the next generation of scientists.

VinFuture: Recognizing transformative science

The 2023 VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and honor the scientists behind the discovery of the role of GLP-1. Following the VinFuture Prize, the GLP-1 research group has continuously received recognitions with numerous other prestigious accolades, including their listing among the 2024 Time 100 Most Influential People.

Reflecting on this, Prof. Drucker expressed deep appreciation, noting that these awards provide invaluable support in pushing the boundaries of scientific discovery.

“As the VinFuture Prize gains prominence, having GLP-1 science acknowledged as a recipient also helps elevate the global understanding of how it can transform healthcare,” he emphasized.

Continuing its commitment to recognizing impactful advancements, the 2024 VinFuture Prize honored innovators in the biomedical field for their development of CAR T-cell therapy for cancer and other diseases. According to Prof. Drucker, this innovation stands as “a remarkable example of how immunological science can revolutionize the treatment of many cancer types.”

“With the honoring of AI and CAR T cell therapy, the trends I observe are consistent with other international awards, where similar innovative themes are celebrated around the same time or within a few years. This alignment reinforces the importance of these breakthroughs.” Prof. Drucker commented.

Among the youngest international science-technology awards, now in its fifth year, the VinFuture Prize is steadily establishing its significance and reputation, evidenced by the increasing number of laureates continuing to receive recognition from prestigious international awards, most notably the Nobel Prize. Prominent examples include Dr. Katalin Karikó and Prof. Drew Weissman (Laureates of the 2021 VinFuture Grand Prize and 2023 Nobel Prize in Physiology or Medicine), Dr. Demis Hassabis and Dr. John Jumper (Laureates of the 2022 VinFuture Special Prize and 2024 Nobel Prize in Chemistry), and Prof. Geoffrey Hinton (Laureate of the 2024 VinFuture Grand Prize and 2024 Nobel Prize in Physics).

“Despite being a relatively new award, the VinFuture Prize has done an exceptional job of highlighting high-quality science. The recognition of AI, coinciding with its recent recognition by the Nobel Prize, highlights its transformative impact on numerous aspects of society,” Prof. Drucker said. “So I think the VinFuture Prize council really has its finger on the leading edge of science in many areas.”

Beyond diabetes

2024 was a landmark year for GLP-1 research, with several exciting clinical trials demonstrating benefits extending far beyond obesity to include the treatment of patients with heart disease, obstructive sleep apnea, and knee osteoarthritis. Additionally, Prof. Drucker hinted at early promising results for patients with metabolic liver disease and noted ongoing studies exploring GLP-1’s effects on Alzheimer’s disease, with results expected soon.

“The continuous wave of new findings will provide deeper insights into the full potential of GLP-1-based therapies.” Prof. Drucker commented, stating that each study will contribute to refining our understanding of this science.

Furthermore, Prof. Drucker highlighted GLP-1’s neurological effects and its potential clinical application in addressing mental health conditions, including anxiety, depression, and compulsive behaviors. He noted that preliminary, early-stage trials with small patient groups investigating GLP-1’s potential in reducing cravings and treating addiction-related disorders have yielded promising initial results.

“Several academic research centers are actively studying GLP-1’s effects on substance use disorders, and major pharmaceutical companies such as Eli Lilly and Novo Nordisk have begun clinical trials to explore these applications further.” Prof. Drucker shared, “It will likely take 12 to 18 months before we gain a clearer picture of whether these medicines can be clinically effective in helping individuals reduce or quit substance use.”

Prof. Drucker also highlighted compelling research indicating GLP-1’s interaction with the brain, extends beyond appetite regulation, suggesting a range of potential therapeutic applications.

“Ongoing trials are underway in people with substance use disorders, including alcohol, nicotine, cannabinoids, and opioids, conditions for which existing medicines are not always very effective.” He elaborated, “We have trials underway for Alzheimer’s disease with oral semaglutide, which are expected to conclude by the end of 2025. These investigations will significantly enhance our understanding of GLP-1’s neurological impact and potential clinical applications.”

Overcome barriers to maximize impact

Despite the global excitement for the “Ozempic era”, there are many challenges hindering the widespread impact for GLP-1 medicines. These include the current high cost and limited accessibility of the treatments, the reliance on primarily two main drug options (semaglutide and tirzepatide), and the practical limitations of refrigeration and pen-based delivery for most formulations, as Prof. Drucker pointed out.

“A key priority is the democratization of these treatments so that everyone who could benefit from them has access. To achieve this, we are working on small-molecule pills that are easier to manufacture and should be more affordable.” He explained.

Prof. Drucker anticipated that increased competition in the GLP-1 market will lead to lower prices, development of newer versions that are easier to use, including once-monthly injections, thereby improving accessibility and convenience for millions worldwide.

“Most initial launches have occurred in countries with well-established healthcare and reimbursement systems. Only now are we seeing manufacturing capacity expand enough to increase availability, but costs remain a significant barrier.” He stated, emphasizing the critical need to advance these medicines not only to enhance their efficacy in areas like weight loss and cardiovascular health but also to make them more convenient to take, more affordable, and more broadly accessible to patients globally.

Another major challenge that Prof. Drucker identified is determining the appropriate dosage for extending the therapeutic applications of GLP-1 to conditions beyond diabetes and obesity. While the dosage effective for weight loss may not be suitable for other disorders like Parkinson’s, Alzheimer’s, alcohol use disorder, anxiety, or depression, understanding the dose-response relationship for these conditions requires time and further investigation.

Additionally, research is underway to reduce adverse effects, making GLP-1 treatments safer and more comfortable for patients. Prof. Drucker elaborated, “One key strategy is starting patients on very low doses and gradually increasing them to minimize side effects. Additionally, some companies are researching ways to reduce further adverse effects, such as developing co-formulated anti-nausea compounds to improve tolerability.”

Future research for GLP-1 therapies presents numerous possibilities; however, the translation from research to clinical application for neurodegenerative and substance use disorder treatments still presents unmet needs with a lack of evidence for progress. According to Prof. Drucker, with clinical trials underway, they may yield valuable insights within the next 12 to 24 months regarding the potential extension of GLP-1 therapy benefits from glucose control to complex disorders of the central nervous system.

He identified, “The key lies in understanding how to effectively engage the brain, identifying which regions can respond to GLP-1 signaling, and how to optimize that communication.”

In conclusion, Prof. Drucker highlighted the promising contemporary landscape of scientific research, emphasizing the crucial need to inspire the next generation to embrace science and pursue research careers. In this context, the 2023 VinFuture Special Prize Laureate commended the VinFuture Prize for its valuable contribution in motivating individuals within the scientific community and engaging younger generations in science.

“When we visited Vietnam, we met with many young scientists, and I was impressed by VinFuture’s strong efforts to inspire and connect with them. I encourage VinFuture to continue and expand these efforts because investing in young talent is the key to a future filled with groundbreaking innovations.” He stated.

Hashtag: #VinFuture

https://vinfutureprize.org/vinfuture-prize-nomination/

The issuer is solely responsible for the content of this announcement.

VinFuture

The VinFuture Foundation, established on International Human Solidarity Day on December 20th, 2020, is a non-profit organization co-founded by billionaire Mr. Pham Nhat Vuong and his wife, Mrs. Pham Thu Huong. The Foundation’s core activity is awarding the annual VinFuture Prize, which recognizes transformative scientific and technological innovations capable of making significant positive changes in the lives of millions of people worldwide.

The nomination period for the 2025 VinFuture Prize will close at 2:00 PM on April 17, 2025 (Vietnam time, GMT+7). Submit your nominations here: https://vinfutureprize.org/vinfuture-prize-nomination/. Outstanding nominators will be honored through the VinFuture Nominator Recognition Program.The VinFuture Prize consists of four prestigious awards presented each year. The most esteemed is the VinFuture Grand Prize, valued at US$3 million, making it one of the largest annual prizes globally. Additionally, there are three Special Prizes, each valued at US$500,000, specifically dedicated to honoring Women Innovators, Innovators from Developing Countries, and Innovators with Outstanding Achievements in Emerging Fields.

Media OutReach

Pan African Visions Journalists Win Prestigious Merck Foundation Awards for Excellence in Health and Social Reporting

Published

23 hours ago

14/04/2025

Media Outreach

BUEA, CAMEROON – Media OutReach Newswire – 14 April 2025 – In a major milestone for African journalism, three reporters from Pan African Visions (PAV) have been honored with international accolades from the Merck Foundation, underscoring the publication’s growing influence and commitment to impactful storytelling on health and social issues across the continent.

As part of their recognition, Esono, Mawire, and Kurupati were inducted into the prestigious Merck Foundation Alumni community – a global network of journalists dedicated to using their platforms to drive health advocacy and positive change

The recognition came during the 2024 Merck Foundation Media Recognition Awards, held virtually on April 10, 2025, under the patronage of Senator Dr. Rasha Kelej, CEO of the Merck Foundation and President of the “More Than a Mother” campaign. These annual awards, in collaboration with First Ladies across Africa, celebrate media professionals who raise awareness and drive positive change in areas such as infertility stigma, women’s empowerment, non-communicable diseases, and gender-based violence.

The winners were announced during a virtual awards ceremony held on April 10, 2025, and presided over by Senator Dr. Rasha Kelej, CEO of the Merck Foundation and President of the “More Than a Mother” campaign which works closely with First Ladies across Africa

Representing Cameroon, Zimbabwe, and the African continent at large, the three award-winning journalists from PAV are:

Boris Esono Nwenfor (Cameroon), PAV’s Bureau Chief, who clinched third place in the “More Than a Mother” 2024 online media category for French-speaking countries. His powerful report, “No Excuse! VAWG Goes against Fundamental Rights of Human Beings,” shone a light on the scourge of violence against women and girls and the advocacy work of CHRDA. This marks his second Merck Foundation award, having previously won in 2021.

Wallace Mawire (Zimbabwe), who earned second place in the Southern Africa category of the “More Than a Mother” awards for his coverage of women’s reproductive health issues and empowerment.

Prince Kurupati (Zimbabwe), who secured third place in the “Diabetes & Hypertension 2024” category for his feature on the importance of lifestyle changes in combating non-communicable diseases.

As part of their recognition, all three were inducted into the Merck Foundation Alumni community, a global network of journalists committed to advancing health advocacy through the media.

“This recognition is humbling and motivating,” said Esono. “Being part of a global network of journalists passionate about health and social justice strengthens our collective voice and deepens our commitment to telling stories that matter.”

PAV’s Managing Editor, Ajong Mbapndah L, lauded the achievements of his team:

“We are incredibly proud of our journalists. These awards are not only a testament to their professionalism and dedication, but also a reflection of Pan African Visions’ mission to amplify African voices and address critical issues impacting our communities. We extend our deep appreciation to the Merck Foundation and Dr. Rasha Kelej for empowering journalists and championing transformative health and gender narratives.”

*We applaud the outstanding work of the Merck Foundation and Dr. Rasha Kelej in promoting health, gender equity, and social justice through journalism, says PAV Managing Editor Ajong Mbapndah L*

This latest milestone adds to Pan African Visions’ impressive track record of recognition. In 2021, journalists Ishmael Koroma and Nevson Mpofu were also awarded by the Merck Foundation, further solidifying PAV’s position as a leading voice in health and development reporting across Africa.

Through its monthly magazine and dynamic news portal www.panafricanvisions.com, PAV continues to drive impactful journalism that connects the African continent, informs global audiences, and fosters dialogue around Africa’s most pressing challenges and opportunities.

Hashtag: #PanAfricanVisions

The issuer is solely responsible for the content of this announcement.

About Pan African Visions

Pan African Visions is an influential pan-African multimedia publication delivering daily news and current affairs through digital content and a monthly print edition. Its coverage spans politics, business, health, culture, development, energy, agriculture, innovation, and various other sectors. PAV aims to provide a deeper understanding of Africa’s potential. The platform fosters collaboration and dialogue, connecting African leaders, entrepreneurs, and experts with potential investors and a worldwide audience.

With over 250,000 monthly digital visitors and print readers, Pan African Visions connects a global audience with African voices through reporting, analysis, and meaningful dialogue. For more information, visit www.panafricanvisions.com.

About Merck Foundation

The Merck Foundation is the philanthropic arm of Merck KGaA, Germany that aims to improve the health and wellbeing of people and advance their lives through science and technology. Its efforts are primarily focused on improving access to quality and equitable healthcare solutions, building healthcare, scientiﬁc research and media capacity and empowering people in STEM with a special focus on women and youth in under-served communities.

The foundation strives to work closely with partners that are African First Ladies, Ministries of Health, Education, Information and Communication, Gender, Academia, Research Institutions, Media and Art in building healthcare capacity and addressing health, social and economic challenges in developing countries and under-served communities.